Saltar al contenido
Merck

28266

Levofloxacin

98.0-102.0% anhydrous basis (HPLC)

Sinónimos:

Levofloxacin Anhydrous, (−)-Ofloxacin

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C18H20FN3O4
Número CAS:
100986-85-4
Peso molecular:
361.37
UNSPSC Code:
51102829
NACRES:
NA.85
PubChem Substance ID:
57648297
MDL number:
MFCD00865049
Beilstein/REAXYS Number:
7327015

Nombre del producto

Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)

InChI

1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)/t10-/m0/s1

SMILES string

OC(C(C1=O)=CN2C(C1=CC(F)=C3N4CCN(C)CC4)=C3OC[C@@H]2C)=O

InChI key

GSDSWSVVBLHKDQ-JTQLQIEISA-N

biological source

synthetic

assay

98.0-102.0% anhydrous basis (HPLC)

form

powder or crystals

color

light yellow-white to yellow-white

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria

mode of action

enzyme | inhibits

Quality Level

200

Gene Information

human ... KCNH1(3756)

¿Está buscando productos similares? Visita Guía de comparación de productos

Categorías relacionadas

Application

Levofloxacin is a broad-spectrum antibiotic used in pharmacokinetic , antibiotic resistance , and resistance prevention studies. Antibiotic against bacterial respiratory tract infections.

Biochem/physiol Actions

Levofloxacin is active against Gram-positive and Gram-negative bacteria. It inhibits DNA gyrase (type II topoisomerase) and topoisomerase IV, thereby inhibiting cell division.

Other Notes

Keep container tightly closed in a dry and well-ventilated place. Keep in a dry place.

Packaging

10mg, 1g, 10g

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Resp. Sens. 1A - Skin Sens. 1A

Clase de almacenamiento

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000488861
0000488861
0000417206
0000417206
0000381693

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Miriam Hurst et al.
Drugs, 62(14), 2127-2167 (2002-09-25)
Levofloxacin is the L-form of the fluoroquinolone antibacterial agent, ofloxacin. In in vitro studies, levofloxacin demonstrated a broad range of activity against Gram-positive and -negative organisms and anaerobes. The drug is more active against Gram-positive organisms than ciprofloxacin, but less
George G Zhanel et al.
Drugs, 62(1), 13-59 (2002-01-16)
The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity against Gram-negative bacilli and improved Gram-positive activity (e.g. against Streptococcus pneumoniae and Staphylococcus aureus) over ciprofloxacin. Ciprofloxacin still maintains the best in vitro activity
Takeshi Hirano et al.
International journal of pharmaceutics, 351(1-2), 113-118 (2007-11-06)
L-Carnitine plays an important role in lipid metabolism by facilitating the transport of long-chain fatty acids across the mitochondrial inner membrane followed by fatty acid beta-oxidation. It is known that members of the OCTN family play an important role in
M H Gotfried et al.
Chest, 119(4), 1114-1122 (2001-04-11)
To determine the steady-state plasma, epithelial lining fluid (ELF), and alveolar macrophage (AM) concentrations of levofloxacin and ciprofloxacin. Multiple-dose, open-label, randomized pharmacokinetic study. Thirty-six healthy, nonsmoking adult subjects were randomized either to oral levofloxacin, 500 or 750 mg once daily
Gregory S Basarab et al.
Scientific reports, 5, 11827-11827 (2015-07-15)
With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance. ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico